New pages
- 12:23, 17 June 2020 TMB-H (hist) [2,841 bytes] Jwarner (talk | contribs) (Created page with "{| class="wikitable" style="float:right; margin-right: 5px;" |- |<div style="background-color: #fee0d1; border: 1px solid #808000; padding: 5px; {{border-radius|16px}}" align=...")
- 08:41, 4 June 2020 Relugolix (Relumina) (hist) [2,415 bytes] PeterYang (talk | contribs) (Created page with "''Approved for use in Japan. Under investigation in United States.'' ==General information== Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reve...")
- 21:19, 16 May 2020 Ripretinib (Qinlock) (hist) [2,435 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/kit-pdgfr-inhibitor-dcc-2618 NCI Drug Dictionary]: An orally...")
- 20:11, 11 May 2020 Selpercatinib (Retevmo) (hist) [1,512 bytes] Jwarner (talk | contribs) (Created page with "==Mechanism of action== From the [NCI Drug Dictionary]: An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene recept...")
- 15:34, 6 May 2020 Non-small cell lung cancer, MET-mutated (hist) [3,414 bytes] PeterYang (talk | contribs) (Created page with "{| class="wikitable" style="text-align:center; width:50%;" !colspan="2" align="center" style="color:white; font-size:125%; background-color:#08519c"|'''Section editor''' |- |s...")
- 15:10, 6 May 2020 Capmatinib (Tabrecta) (hist) [2,556 bytes] PeterYang (talk | contribs) (FDA approval)
- 15:18, 2 May 2020 Daratumumab and hyaluronidase (Darzalex Faspro) (hist) [3,089 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism: Anti-CD38 antibody, human monoclonal IgG1 kappa. Daratumumab binds to CD38 and causes apoptosis in CD38-expressing cells via Fc media...")
- 20:37, 24 April 2020 Pemigatinib (Pemazyre) (hist) [1,167 bytes] Jwarner (talk | contribs) (Created page with "==General information== Class/mechanism from the [https://www.cancer.gov/publications/dictionaries/cancer-drug/def/fgfr-inhibitor-incb054828 NCI Drug Dictionary]: An orally bi...")
- 09:44, 18 April 2020 University of Cincinnati Medical Center Hematology Oncology Fellowship (hist) [1,260 bytes] PeterYang (talk | contribs) (Created page with "'''<big>For information about other programs, please visit the Hematology Oncology Fellowship Programs Directory.</big>''' '''People affiliated with this program are cord...")
